** Shares of cancer diagnostic maker Grail GRAL.O falls 3% to $37.16
** Ningi Research says it is short on Grail's position citing co's "overly ambitious approach" to cancer screening that has created "insurmountable regulatory roadblocks"
** "We believe Grail's cancer detection test is backed by data that is just enough to create investor hype, but far too weak to convince experts, regulators, or insurers of its clinical utility," says Ningi in its report
** Ningi says co's actual sales have "massively underperformed projections"
** GRAL stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。